This inventor holds 2 USPTO granted patents. Top assignees: Unversität Zürich, Wayne State University. Active years: 2022.
Company Filing History:
2 out of 276 
2 out of 602 
Years Active: 2022
Title: Erik C Bottger: Innovator in Antibacterial Drug Development
Introduction
Erik C Bottger is a prominent inventor based in Zurich, Switzerland. He has made significant contributions to the field of antibacterial drug development, particularly through his innovative work on aminoglycoside antibiotics. With a total of 2 patents, Bottger's inventions focus on enhancing the efficacy of existing antibacterial agents.
Latest Patents
One of Bottger's latest patents involves apramycin derivatives. This invention relates to derivatives of apramycin-based aminoglycoside antibacterial drugs modified in positions C5 and/or C6 and O5 and/or O6. The modifications impart favorable properties regarding increased selectivity and retention of activity in the presence of resistance determinants of the AAC(3) class. The invention further relates to these compounds for use in the therapy of bacterial infections by systemic administration, especially in instances where the infection is caused by a pathogen comprising a resistance determinant of the AAC(3) class, particularly AAC(3)-IV. Another significant patent pertains to neomycin and paromomycin derivatives. This disclosure relates to derivatives of neamine-based aminoglycoside antibacterial drugs modified in position C6', C2′, and/or C5″. The modifications impart favorable properties regarding activity against ESKAPE pathogens, evasion of resistance traits, and increased selectivity, enabling systemic use of the compounds.
Career Highlights
Throughout his career, Erik C Bottger has worked with esteemed institutions such as Wayne State University and Universität Zürich. His research has focused on developing innovative solutions to combat bacterial resistance, making him a key figure in the field of microbiology and pharmacology.
Collaborations
Bottger has collaborated with notable professionals in his field, including David Crich and Amr Sonousi. These collaborations have further enhanced his research and contributed to the advancement of antibacterial therapies.
Conclusion
Erik C Bottger's work in the development of aminoglycoside antibiotics showcases his commitment to addressing critical challenges in bacterial resistance. His innovative patents and collaborations highlight his significant impact on the field of antibacterial drug development.